SCHEMBL5947283

SCHEMBL5947283

Clc1cccc(CCNCc2cccc(Oc3ccccc3)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 6/20 0.58
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ CHRM2 P08172 1/20 0.55
▸ ADRB3 P13945 3/20 0.54
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ HTT P42858 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ LTA4H P09960 1/20 0.51
▸ EPHX2 P34913 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ ADRB1 P08588 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947523 0.93 CYP1A2 (0.56) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947135 0.90 CYP1A2 (0.56) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947298 0.90 CYP1A2 (0.52) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947462 0.90 KDM4E (0.62) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947672 0.90 CYP1A2 (0.70) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947405 0.90 CYP1A2 (0.52) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947215 0.89 BCHE (0.62) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947718 0.88 BCHE (0.72) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947594 0.88 CYP1A2 (0.64) BCHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947496 0.88 CYP1A2 (0.53) BCHECYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B BCHE 763/4885CYP1A2 530/4885CYP3A4 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback